prma digital applications

Drive readiness for HTA submissions for your Phase 2 and 3 products

The PRMA Healthcheck® late module is a digital application that uses actual HTA templates to evaluate commercial and access risks and opportunities. It streamlines processes and aligns global and local market perspectives.

Bring a clear understanding of the risks and opportunities in multiple markets based on a robust situation analysis
Encourage integrated decision-making between affiliate and global functions to build an evidence generation plan
Generate an organizational vision and action plan to anticipate and mitigate value challenges to optimize payer readiness

Providing insight

  • Bring a clear understanding of the risks and opportunities in multiple markets based on a robust situation analysis

  • Match evidence to HTA payer templates and requirements to identify gaps

  • Focus attention on the key issues that you can’t afford to ignore

Enhancing collaboration

  • Integrate affiliate needs by providing a framework based on current HTA payer templates

  • Prompt earlier and effective communication using a visual heatmap of evidence gaps

  • Encourage cross-functional collaboration to align on issues

Driving action

  • Link risk assessments to a comprehensive evidence generation plan

  • Identify actions to mitigate risk

  • Prioritize activities across markets


Digital technology is transforming pharmaceutical market access

Read how

Top-10 pharmaceutical and biotechnology manufacturers have transformed their strategic market access processes with the PRMA Healthcheck® late module

These case studies demonstrate how the unique digital application has helped to:

accelerate evaluation of commercial and access risks and opportunities

streamline processes

align global and local market perspectives.


How is technology disrupting pharmaceutical and biotechnology market access?

Read more

Pharmaceutical and biotechnology companies are turning to technology more frequently to solve business issues, and optimize market access for their products. We believe that there are three key benefits of digital transformation for biopharma value and access functions.

Case studies

Assessing evidence generation strategies for an asset with a novel biomarker in a rapidly evolving landscape

Identifying critical risks for payer decision-making

Critically evaluating pricing and access risks and opportunities for an asset under different clinical development scenarios

Reviewing and strengthening payer evidence readiness for Phase 2 products

Demonstrating value using a new approach to economic modeling

A consumate piece of analysis with astute outputs, I look forward to making good use of it.
Senior Market Access Manager, top-5 pharmaceutical company

The work culminated in a very successful early launch meeting with live market feedback and sharing of early global strategy.
Director, Global HEOR, top-20 pharmaceutical company

Request a demonstration

Our user friendly applications and expert team have supported organizations around the world in achieving their goals. We are always happy to have an informal, confidential chat and help you re-think your market access challenges.

First name *

* Please enter your first name

Last name *

* Please enter your last name

Email *

* Please enter an email address
UK (HQ) +44 (0)1252 786284
US +1 (415) 655 6798

Company registration number: 05893400

Follow us